DrugPatentWatch Database Preview
Genentech Inc Company Profile
» See Plans and Pricing
US Patents for Genentech Inc
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech Inc | PHESGO | pertuzumab;trastuzumab;hyaluronidase-zzxf | INJECTABLE;SUBCUTANEOUS | 761170 | 001 | 2020-06-29 | RX | |||||
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | RE46856 | Bayer Intellectual Property GMBH (Monheim, DE) | 2026-12-05 | RX | search | |
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | 9,994,550 | 3-V Biosciences, Inc. (Menlo Park, CA) | 2034-01-07 | RX | search | |
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | 9,993,568 | LegoChem Biosciences, Inc. (Daejeon, KR) | 2034-05-28 | RX | search | |
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | 9,993,530 | Bioasis Technologies, Inc. (Guilford, CT) | 2033-03-13 | RX | search | |
| Genentech Inc | HERCEPTIN HYLECTA | trastuzumab; hyaluronidase-oysk | INJECTABLE;SUBCUTANEOUS | 761106 | 001 | 2019-02-28 | 9,987,416 | 2039-02-26 | RX | search | ||
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
Similar Applicant Names
Companies are sometimes listed under multiple names.
This search can help find similar names.
This search can help find similar names.
